Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 9 newly-hired employees options to purchase an aggregate of 197,200 shares of Akebia’s common stock on April 30, 2021, as inducements material to each such employee’s entering into employment with Akebia.